THE European Medicines Agency says it is urgently reviewing multiple sclerosis medicine Zinbryta (daclizumab) after seven cases of serious inflammatory brain disorders in Germany and Spain.
Biogen Idec Limited, the company that markets Zinbryta, has also informed the EMA of its intention to voluntarily withdraw the drug's marketing authorisations and stop ongoing clinical studies with Zinbryta in the European Union.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Mar 18
